A securities class action has been filed against Inovio Pharmaceuticals, Inc. alleging the company made misleading statements to investors regarding its CELLECTRA device manufacturing capabilities and the regulatory trajectory of its INO-3107 program. According to the complaint, Inovio failed to adequately disclose material manufacturing deficiencies that contributed to a one-year delay in submitting its Biologics License Application to the FDA.
The regulatory setback materialized when the FDA accepted the BLA under a standard review pathway rather than the accelerated review timeline investors had anticipated. This determination coincided with a sharp decline in the company's stock price, which fell 24.45% on December 29, 2025, following the announcement. The significant equity loss prompted investors to pursue class action litigation, contending that the non-disclosure of manufacturing issues and regulatory complications constituted violations of federal securities laws.
Investors who held Inovio securities during the relevant period have until April 7, 2026 to file a lead plaintiff motion in the case. The deadline marks a critical juncture for shareholders seeking to participate in the litigation or assume a leadership role in the class action proceeding.